Hsbc Holdings PLC Takes $753,000 Position in Amphastar Pharmaceuticals, Inc. $AMPH

Hsbc Holdings PLC bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 38,017 shares of the company’s stock, valued at approximately $753,000. Hsbc Holdings PLC owned approximately 0.09% of Amphastar Pharmaceuticals at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Quarry LP purchased a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at $32,000. Farther Finance Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals by 46.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock worth $37,000 after buying an additional 437 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Amphastar Pharmaceuticals by 37.8% in the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock worth $45,000 after buying an additional 462 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Amphastar Pharmaceuticals by 24.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after acquiring an additional 435 shares during the last quarter. Finally, TD Private Client Wealth LLC increased its holdings in Amphastar Pharmaceuticals by 410.1% during the 4th quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock valued at $65,000 after acquiring an additional 1,944 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AMPH. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Barclays cut their price objective on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a research report on Wednesday, June 3rd. Bank of America reaffirmed an “underperform” rating and issued a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $19.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Six research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals currently has a consensus rating of “Reduce” and an average target price of $22.00.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH opened at $20.58 on Thursday. The firm has a market cap of $907.37 million, a price-to-earnings ratio of 12.40, a price-to-earnings-growth ratio of 4.25 and a beta of 0.89. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79. The company’s 50-day moving average is $19.46 and its two-hundred day moving average is $21.72. Amphastar Pharmaceuticals, Inc. has a 12-month low of $16.65 and a 12-month high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The firm had revenue of $171.17 million for the quarter, compared to analysts’ expectations of $173.46 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%. Research analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.25 EPS for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.